Lloyd M. Segal

President & CEO

Lloyd M. Segal has served as our President and Chief Executive Officer and as a member of our board of directors since our incorporation in September 2016. From February 2010 to January 2016, he was a Managing Partner with Persistence Capital Partners, a Canadian-based healthcare private equity investor. Previously, Mr. Segal was a consultant with McKinsey & Company, and served as chief executive officer of several emerging biotechnology companies including Advanced Bioconcept Inc., Caprion Pharmaceuticals Inc. (now Caprion Biosciences), which he co-founded, and Thallion Pharmaceuticals Inc.

+ Show More

Steve Forte

EVP, Chief Financial Officer

Steve Forte has served as our Executive Vice President, Chief Financial Officer since October 2019. Prior to joining us, he served as Chief Financial Officer of Clementia Pharmaceuticals Inc. from August 2018 through June 2019, during which time Clementia was acquired by Ipsen S.A. From September 2015 to August 2018, Mr. Forte served as Chief Financial Officer of Thinking Capital Financial Corporation, a Canadian financial technology firm, where he ultimately led the firm through a sale to Purpose Investments.

+ Show More

Philip Herman

EVP, Commercial & New Product Development

Phil Herman has served as our EVP, Commercial and New Product Development since January of 2022. Mr. Herman brings extensive commercial experience with a focus in oncology and rare diseases and has a proven track record of product launches across a broad spectrum of therapeutic areas.

Mr. Herman most recently served as the Chief Commercial Officer of Y-mAbs Therapeutics where he led the successful launch and commercialization of DANYELZA® (naxitamab). He served in this role from June 2018 to December 2021. Prior to Y-mAbs, Mr. Herman held various commercial and marketing positions including VP, Head of Santhera U.S. and Head of Commercial, Head of Marketing at Dyax, Director of Marketing at Vanda Pharmaceuticals, and various positions of increasing responsibility at Pfizer Inc.

+ Show More

Maria Koehler, M.D., Ph.D.

EVP & Chief Medical Officer

Maria Koehler, M.D., Ph.D. has served as our Executive Vice President, Chief Medical Officer since May 2019. Prior to joining us, from September 2017 to April 2019, Dr. Koehler served as the Chief Medical Officer of Bicycle Therapeutics Limited. From March 2009 to September 2017, Dr. Koehler served as Vice President of Strategy, Innovation and Collaborations for the Oncology Business Unit at Pfizer Inc. Prior to joining Pfizer, Dr. Koehler was the group leader for the Medicine Development Center of GlaxoSmithKline Oncology.

+ Show More

Michael Zinda, Ph.D.

EVP, Chief Scientific Officer

Michael Zinda, Ph.D. has served as our Executive Vice President, Chief Scientific Officer since May 2019 and previously served as Executive Vice President, Head of Research and Development of our U.S. subsidiary, Repare Therapeutics USA Inc., from June 2017 to May 2019. Prior to joining us, he spent 16 years at AstraZeneca from 2001 to May 2017, where he obtained the position of Executive Director, Head of Cancer Bioscience.

+ Show More

Cameron Black, Ph.D.

EVP, Discovery

Cameron Black, Ph.D. has served as our Executive Vice President, Discovery since June 2016. Prior to joining us, Dr. Black co-founded Kanyr Pharma in 2013 and Kaneq Pharma in 2010 to develop drugs targeting cancer and metabolic disease, respectively. Prior to that, he spent nearly two decades at the Merck Frosst Center for Therapeutic Research, where he was responsible for the identification of seven drug candidates.

+ Show More

Kim Seth, Ph.D.

EVP, Head of Business & Corporate Development

Kim Seth, Ph.D. has served as our Executive Vice President, Head of Business & Corporate Development since June 2017. Prior to joining us, from July 2015 to May 2017, he served as Chief Business Officer, and Chief Operating Officer at Resilience Therapeutics, Inc., where he was a co-founder and member of the Board of Directors. From February 2014 to January 2015, Dr. Seth served as Senior Vice President and Chief Business Officer at Epirus Pharmaceuticals, Inc., and from January 2011 to February 2014, he served as Executive Director, Worldwide R&D, at Pfizer Inc., where he held both global operational and strategy leadership positions.

+ Show More